Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Rexahn Pharmaceuticals Inc.

    Client Virtual Booth

    REXAHN PHARMACEUTICALS INC

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Rexahn Pharmaceuticals Inc
    United_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    15245 Shady Grove Road, Suite 455 Rockville, MD 20850
    Telephone
    Telephone
    + 240-268-5300
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://rexahn.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/rexahn-pharmaceuticals/?originalSubdomain=in
    Twitter
    Twitter
    https://twitter.com/rexahnpharma

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Rexahn and Ocuphire Enter into Definitive Merger Agreement

    Details:

    This merger supports Ocuphire for advancement of its late-clinical stage small molecule ophthalmic pipeline including its Nyxol® Eye Drops, a once-daily eye drop formulation of phentolamine mesylate designed to reduce pupil diameter and improve visual acuity.


    Lead Product(s): Phentolamine Mesylate

    Therapeutic Area: Ophthalmology Product Name: Nyxol

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Ocuphire Pharma

    Deal Size: $21.1 million Upfront Cash: Undisclosed

    Deal Type: Merger June 18, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Rexahn Pharmaceuticals Terminates Breast Cancer Study with Merck

    Details:

    The company had previously disclosed that it was evaluating the development strategy for RX-5902, including whether to proceed with the trial.


    Lead Product(s): RX-5902

    Therapeutic Area: Oncology Product Name: Undisclosed

    Highest Development Status: Phase IIProduct Type: Small molecule

    Recipient: Merck & Co

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Termination April 09, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search